Achieve Life Sciences (ACHV) to Release Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is set to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.06. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Stock Up 3.5 %

ACHV stock opened at $4.73 on Wednesday. The company has a debt-to-equity ratio of 4.02, a current ratio of 0.82 and a quick ratio of 0.82. The firm’s fifty day simple moving average is $4.50 and its 200-day simple moving average is $4.47. Achieve Life Sciences has a 12 month low of $3.03 and a 12 month high of $10.30. The company has a market capitalization of $162.00 million, a P/E ratio of -3.09 and a beta of 1.26.

Analyst Ratings Changes

Several research firms have commented on ACHV. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Achieve Life Sciences in a report on Monday, April 1st. Jonestrading assumed coverage on Achieve Life Sciences in a research note on Wednesday, April 17th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Lake Street Capital reduced their price target on Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, March 5th.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.